Chemours Company (The) (NYSE:CC)‘s stock had its “buy” rating reaffirmed by research analysts at Argus in a research note issued on Thursday. They presently have a $55.00 target price on the specialty chemicals company’s stock, up from their previous target price of $50.00. Argus’ price objective suggests a potential upside of 23.85% from the company’s current price.

A number of other equities research analysts also recently commented on the stock. UBS AG upgraded shares of Chemours Company (The) from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $36.00 to $50.00 in a report on Monday. J P Morgan Chase & Co raised their target price on shares of Chemours Company (The) to $55.00 and gave the stock an “overweight” rating in a research report on Friday, August 4th. Citigroup Inc. raised their target price on shares of Chemours Company (The) from $45.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. Jefferies Group LLC raised their target price on shares of Chemours Company (The) to $60.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, Zacks Investment Research raised shares of Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $51.00 target price on the stock in a research report on Friday, July 14th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $51.50.

Chemours Company (NYSE:CC) traded down 4.02% during trading on Thursday, reaching $44.41. 2,614,643 shares of the company were exchanged. The stock has a 50 day moving average price of $43.03 and a 200 day moving average price of $37.85. Chemours Company has a 12 month low of $10.90 and a 12 month high of $51.51. The firm has a market capitalization of $8.21 billion, a PE ratio of 29.06 and a beta of 3.63.

Chemours Company (The) (NYSE:CC) last posted its earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.02. The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.49 billion. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same period last year, the firm posted $0.27 EPS. On average, analysts expect that Chemours Company will post $3.55 EPS for the current fiscal year.

WARNING: “Chemours Company (The) (CC) Earns Buy Rating from Argus” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/10/chemours-company-the-cc-earns-buy-rating-from-argus.html.

In other news, insider Paul Kirsch sold 19,036 shares of the business’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $41.42, for a total transaction of $788,471.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Erich Parker sold 4,908 shares of the business’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total transaction of $223,461.24. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Cypress Capital Management LLC WY boosted its position in Chemours Company (The) by 1.9% in the first quarter. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company’s stock worth $162,000 after buying an additional 80 shares during the last quarter. Charter Trust Co. boosted its position in Chemours Company (The) by 2.1% in the second quarter. Charter Trust Co. now owns 5,720 shares of the specialty chemicals company’s stock worth $217,000 after buying an additional 120 shares during the last quarter. Advisor Partners LLC boosted its position in Chemours Company (The) by 1.4% in the first quarter. Advisor Partners LLC now owns 9,821 shares of the specialty chemicals company’s stock worth $378,000 after buying an additional 140 shares during the last quarter. Neuberger Berman Group LLC boosted its position in Chemours Company (The) by 1.5% in the first quarter. Neuberger Berman Group LLC now owns 9,579 shares of the specialty chemicals company’s stock worth $369,000 after buying an additional 141 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Chemours Company (The) by 0.6% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 26,921 shares of the specialty chemicals company’s stock worth $1,021,000 after buying an additional 167 shares during the last quarter. 75.21% of the stock is currently owned by institutional investors and hedge funds.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Analyst Recommendations for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.